Article By:
Fred Fuld III
Sunday, June 25, 2023 3:01 PM EDT
CRISPR Therapeutics continues to be at the forefront of CRISPR-based therapeutics development. It's the first, and largest, but not the only player.
Editas Medicine, Inc., Announces Pricing Of $50 Million Offering Of Common Stock
Looking forward to hearing more information about $EDIT. Company seems to operate in a very exiting and potentially fast growing new field.